ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 259.4 | 180.3 | 197.7 |
| Other income | 5.0 | 2.5 | 4.1 |
| Total income | 264.4 | 182.8 | 201.7 |
| Profit before exceptional items & tax | 61.6 | 33.5 | 31.0 |
| Profit before tax | 61.6 | 33.5 | 31.0 |
| Net profit | 47.5 | 25.6 | 21.0 |
| Operating margin | 23.3% | 18.3% | 15.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +126.20% |
|---|---|
| Net profit, quarter on quarter | +85.50% |
| Revenue, year on year | +31.20% |
BSE results filing, NSE: VENUSREM. Figures extracted from the filing.
Venus Remedies Ltd: key numbers
- Share price
- ₹1,447.90
- Market cap
- ₹1,935 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 15.9×Sector 43.8×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venus Remedies Ltd
All →Venus Remedies Other Announcement
Venus Remedies relayed social media posts about a SEBI special window for re-lodging physical share transfer requests. The notice carries no monetary event.
Venus Remedies Q2 FY27 Results: Net Profit ₹25.6 Cr, Up 27.4% YoY
Venus Remedies Ltd reported revenue from operations of ₹218.8 Cr (+13.5% YoY) and net profit of ₹25.6 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹25.6 Cr · +27.4% YoY
Venus Remedies Regulatory Approval
Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.
Venus Remedies Board Meeting Date
Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.
Venus Remedies Other Announcement
Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Venus Remedies Other Announcement
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.